title: Antimicrobial activity of mul-1867, a novel antimicrobial compound, against multidrug-resistant Pseudomonas aeruginosa.
abstract: BACKGROUND
  There is an urgent need for new antimicrobial compounds to treat various lung infections caused by multidrug-resistant Pseudomonas aeruginosa (MDR-PA).
  
  
  METHODS
  We studied the potency of Mul-1867 against MDR-PA isolates from patients with cystic fibrosis, chronic obstructive pulmonary disease, and ventilator-associated pneumonia. The minimal inhibitory concentrations (MICs) and minimum biofilm eliminating concentrations (MBECs), defined as the concentrations of drug that kill 50 % (MBEC50), 90 % (MBEC90), and 100 % (MBEC100) of the bacteria in preformed biofilms, were determined by using the broth macrodilution method.
  
  
  RESULTS
  Mul-1867 exhibited significant activity against MDR-PA and susceptible control strains, with MICs ranging from 1.0 to 8.0 µg/mL. Mul-1867 also possesses anti-biofilm activity against mucoid and non-mucoid 24-h-old MDR-PA biofilms. The MBEC50 value was equal to onefold the MIC. The MBEC90 value ranged from two to fourfold the MIC. Moreover, Mul-1867 completely eradicated mature biofilms at the concentrations tested, with MBEC100 values ranging between 16- and 32-fold the MIC. Mul-1867 was non-toxic to Madin-Darby canine kidney (MDCK) cells at concentrations up to 256 µg/mL.
  
  
  CONCLUSIONS
  Overall, these data indicate that Mul-1867 is a promising locally acting antimicrobial for the treatment and prevention of P. aeruginosa infections.
authors.affiliation: TGV-Laboratories LLC, 303 5th avenue, # 2012, New York, NY, 10016, USA. georgetets@gmail.com.
authors.forename: George
authors.initials: G
authors.lastname: Tetz
authors.affiliation: Institute of Human Microbiology, New York, NY, 10016, USA.
authors.forename: Daria
authors.initials: D
authors.lastname: Vikina
authors.affiliation: Institute of Human Microbiology, New York, NY, 10016, USA.
authors.forename: Victor
authors.initials: V
authors.lastname: Tetz
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000494:pharmacology*; D018441:Biofilms / Q000187:drug effects; D002460:Cell Line; D003550:Cystic Fibrosis / Q000150:complications; D004285:Dogs; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D008826:Microbial Sensitivity Tests; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000209:etiology / Q000382:microbiology*; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000254:growth & development / Q000502:physiology
chemical_list: D000900:Anti-Bacterial Agents
keywords: Biofilms; Cystic fibrosis; Mucoid; Multidrug-resistant; Non-mucoid; P. aeruginosa